| Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3: cardiovascular topic RF Kelly-Laubscher, JC King, D Hacking, S Somers, S Hastie, T Stewart, ... Cardiovascular journal of Africa 25 (3), 118-123, 2014 | 23 | 2014 |
| Sphingosine-1-phosphate (S1P) activates STAT3 to protect against de novo acute heart failure (AHF) GP Deshpande, A Imamdin, S Lecour, LH Opie Life sciences 196, 127-132, 2018 | 16 | 2018 |
| Exploring the role of serotonin as an immune modulatory component in cardiovascular diseases A Imamdin, EPC van der Vorst International Journal of Molecular Sciences 24 (2), 1549, 2023 | 6 | 2023 |
| RIC in COVID-19—a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19 SM Davidson, K Lukhna, DA Gorog, AD Salama, AR Castillo, S Giesz, ... Cardiovascular Drugs and Therapy 36 (5), 925-930, 2022 | 3 | 2022 |
| Doxorubicin-induced cardiotoxicity and risk factors C Belger, C Abrahams, A Imamdin, S Lecour IJC Heart & Vasculature 50, 101332, 2024 | 1 | 2024 |
| Effect of remote ischaemic conditioning on the inflammatory cytokine cascade of COVID-19 (RIC in COVID-19): a randomized controlled trial K Lukhna, HRP do Carmo, AR Castillo, SM Davidson, H Geffen, S Giesz, ... Cardiovascular Drugs and Therapy, 1-13, 2022 | 1 | 2022 |
| RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19 (Jun, 10.1007 … SM Davidson, K Lukhna, DA Gorog, AD Salama, AR Castillo, S Giesz, ... CARDIOVASCULAR DRUGS AND THERAPY 36 (5), 931-931, 2022 | | 2022 |
| Correction to: RIC in COVID-19—a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19 SM Davidson, K Lukhna, DA Gorog, AD Salama, AR Castillo, S Giesz, ... Cardiovascular Drugs and Therapy, 2021 | | 2021 |
| Prognostic value of NT-pro-BNP for myocardial recovery in peripartum cardiomyopathy KS J Hoevelmann, CA Viljoen, F Azibani, A Imamdin, S Kraus, J Cirota, O ... European Heart Journal 41 (Supplement 2), ehaa946.3185, 2020 | | 2020 |
| SAFE pathway and conditioning: from discovery to its effectiveness in the presence of cardiovascular risk factors A Imamdin, N Hadebe, S Lecour Conditioning Medicine 3 (2), 98 - 103, 2020 | | 2020 |
| Targeting heart rate as a novel therapeutic approach in acute heart failure A Imamdin | | 2018 |
| Heart rate–a novel target for treatment of peripartum cardiomyopathy? A Imamdin, S Lecour, LH Opie, K Sliwa, F Azibani SA Heart 13 (4), 304-307, 2016 | | 2016 |
| Heart rate as a novel target for peripartum cardiomyopathy? KS Aqeela Imamdin, Sandrine Lecour, Lionel Opie SA Heart congress 2016 13 (3), 192, 2016 | | 2016 |
| Exploration of Signalling Molecule Interactions to Protect Against a Heart Attack and Heart Failure, Using STAT3 Deficient & PKC Over-expressing Mice A Imamdin University of Cape Town, 2013 | | 2013 |
| Exploration of signalling molecule interactions involved in heart failure using STAT3 deficient & PKC overexpressing mouse models A Imamdin | | 2013 |
| IJC Heart & Vasculature C Belger, C Abrahams, A Imamdin, S Lecour | | |
| Conditioning Medicine R Lourens, A Imamdin, S Lecour | | |
Sandrine LecourProfessor, University of Cape TownVerified email at uct.ac.za
